Interplay Between Oncomicrobes, the Microbiota and the Immune System: Impact on Responses to Cancer Immunotherapy
Cancer immunotherapies harness the power of the immune system to target cancer cells that express tumor-associated antigens. Immune checkpoint inhibitors, such as monoclonal antibodies against inhibitory T cell receptors, i.e., PD-1/PD-L1 and CTLA-4, allow cancer...
Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 American Society for Clinical Oncology...
Researchers are harnessing the microbiome to modulate treatment response
“You are what you eat” is more than a catchy aphorism. In cancer treatment response, it is the literal truth: Altering the composition of the gut microbiome can change response to some chemotherapy and immunotherapy regimens, and altering the tumor microbiome can have...
